NSC 401366

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: NSC 401366
• 英文别名: 1-methyl-5-[9]phenanthryl-biguanide；1-Methyl-5-[9]phenanthryl-biguanid；N-methyl-N''-9-phenanthrylimidodicarbonimidic diamide；(1E)-1-[amino-(phenanthren-9-ylamino)methylidene]-2-methylguanidine
• 化学式: C₁₇H₁₇N₅
• 分子量: 291.355
• InChiKey: HPIFGVIJVOGIGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  88.8
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-氰基-N'-甲基-胍 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 作用下， 生成 NSC 401366
  参考文献：
  名称：

  May, Journal of Organic Chemistry, 1947, vol. 12, p. 440 Anm.6

  摘要：

  DOI：

文献信息

• Method for treating cancer using chemokine antagonists
  申请人：Syntrix Biosystems Inc.

  公开号：US10660909B2

  公开（公告）日：2020-05-26

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.

  所描述的是一种通过使用 CXCR1 和/或 CXCR2 受体拮抗剂治疗需要此类治疗的患者癌症的方法，其方法是施用治疗有效量的 CXCR1 和/或 CXCR2 拮抗剂或其药物组合物，既可单独作为单一疗法，也可与至少一种其他抗癌疗法联合使用。
• Therapeutic compositions and methods of making and using the same
  申请人：Advanced ReGen Medical Technologies, LLC

  公开号：US10717981B2

  公开（公告）日：2020-07-21

  Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.

  本文公开了多核苷酸制剂（包括干扰 RNA 制剂 (RNAi)）、小分子制剂和合成细胞、制作方法，以及它们作为治疗与年龄相关的功能障碍和/或导致各种疾病状态的细胞功能障碍的用途。在一些实施方案中，本文公开的一种或多种制剂可用于靶向和/或降低配对盒蛋白 5（PAX5）基因、蛋白磷酸酶、Mg2+/Mn2+依赖性 1F（PPM1F）基因或两者的表达。本文还公开了利用一种或多种细胞因子、多核苷酸制剂和/或小分子制剂，通过体外和/或体内操作制备和使用合成细胞的方法。本文公开了这些细胞作为治疗细胞的用途，可治疗与年龄有关的功能障碍和/或导致各种疾病状态的细胞功能障碍。
• INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS
  申请人：Chen Wei

  公开号：US20090155311A1

  公开（公告）日：2009-06-18

  The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.
• METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
  申请人：Syntrix Biosystems Inc.

  公开号：US20180177808A1

  公开（公告）日：2018-06-28

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
• THERAPEUTIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
  申请人：Advanced ReGen Medical Technologies, LLC

  公开号：US20190218558A1

  公开（公告）日：2019-07-18

  Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg 2+ /Mn 2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.